Objective:To observe clinical efficacy of Edaravone combined with Xueshuantong in treatment of cerebral infarc-tion. Methods:A retrospective analysis of the clinical data of 200 cases with cerebral infarction was done. All patients were divided in-to observation group and control group, wherein observation group was treated with Xueshuantong combined with Edaravone, while con-trol group was treated with Edaravone. National institute of health stroke scale ( NIHSS) scores before and after the treatment and the efficacy 4 weeks after the treatment were analyzed. Results:4 weeks after the treatment, the NIHSS scores of observation group and control group both significantly decreased. The NIHSS scores of observation group were significantly higher than those of control group before and after the treatment, and the differences were statistically significant (P<0. 05). Conclusions: Edaravone combined with Xueshuantong in the treatment of cerebral infarction has significant clinical effects, can effectively relieve symptoms, and is worthy of promotion.%目的：观察依达拉奉联合血栓通治疗脑梗死的临床疗效。方法：回顾性分析200例脑梗死患者临床资料，将其分为观察组和对照组，观察组采用依达拉奉联合血栓通治疗，对照组采用依达拉奉治疗。分析两组患者治疗前后神经功能缺失评分( NIHSS)及治疗4周后的疗效。结果：观察组与对照组患者治疗4周后的NIHSS评分均显著降低，且观察组治疗前后评分变化显著高于对照组，差异具有统计学意义(P<0.05)。结论：依达拉奉联合血栓通治疗脑梗死的临床疗效显著，值得临床推广。
展开▼
